Continuous subcutaneous insulin infusion devices, commonly called insulin pumps, have been used for the treatment of patients with type 1 diabetes for several years. The benefits on glycemic control and on the quality of life of these patients are clear and well documented in the literature. On the other hand, their use in insulin-requiring patients with type 2 diabetes is less widespread. However, studies have shown that this therapeutic option is safe and effective for this population as well. In all cases, individualized assessment and follow-up by a specialized multidisciplinary care team is necessary to support patients with type 2 diabetes for whom an insulin pump is considered. We propose to describe here the current state of this clinical practice.